ImmunoCellular Therapeutics Ltd news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

IMUC 0.461 -0.019 (-3.98%)
price chart
ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences ...
NEW YORK, May 5, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, President and Chief Executive Officer, will present live at VirtualInvestorConferences.
ImmunoCellular Therapeutics Ltd (IMUC) Bullish Stance Reiterated at Roth ...
Roth Capital's healthcare analyst Joseph Pantginis weighed in today with a few insights on ImmunoCellular Therapeutics Ltd (NYSE MKT:IMUC), after the company reported full-year 2014 results, posting EPS of ($0.16) compared to Pantginis' estimate of ...
ImmunoCellular's (IMUC) CEO Andrew Gengos on Q4 2014 Results - Earnings ...  Seeking Alpha (registration)
Roth Capital Begins Coverage on ImmunoCellular Therapeutics (IMUC)  sleekmoney
ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of ...
LOS ANGELES, Feb. 12, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it has priced an underwritten public offering of an aggregate of 26,650,000 shares of its common stock at a price ...
Buzz Socks: Expedia (EXPE), Panera Bread (PNRA), ImmunoCellular ...  Wall Street Observer
Positive Trends For ImmunoCellular Therapeutics (IMUC)
Since my previous article on ImmunoCellular Therapeutics (NYSEMKT:IMUC), I have received numerous questions on IMUC. This article will address the most frequently asked and most pointed of those questions.
Related articles »  
Update: Short Interest of ImmunoCellular Therapeutics, Ltd. Drops by -1%
ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) has seen a shortfall of 8,194 shares or 1% in the short interest. The remaining shorts are 1% of the total floated shares.
Noticeable Micro Cap Stocks - ImmunoCellular Therapeutics Ltd (IMUC ...  Investor Wired
Morning Buzz: ImmunoCellular Therapeutics Ltd (IMUC), Merrimack ...
Shares of ImmunoCellular Therapeutics Ltd (IMUC) are up almost 14% to $1.03 in pre-market trading Wednesday after the company announced that it has established a licensing agreement with the California Institute of Technology (Caltech) for exclusive ...
Related articles »  
ImmunoCellular Therapeutics: Potential Near-Term Upward Spike (IMUC)
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is developing novel cancer vaccine immunotherapies for the treatment of brain, ovarian and other solid tumors.
ImmunoCellular Therapeutics Strengthens Executive Management Team with ...
LOS ANGELES, Feb. 18, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the appointment of Steven J. Swanson, PhD, as Senior Vice President, Research.
ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th
LOS ANGELES, March 3, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business ...
ImmunoCellular Therapeutics Receives Positive Regulatory Feedback from ...
LOS ANGELES, Dec. 1, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the European Medicines Agency (EMA) has provided scientific advice supportive of advancing ICT-107 to a ...
Related articles »